PHARMACY

Shoppers Drug Mart donation to support Blueprint for Pharmacy initiative

BY Antoinette Alexander

TORONTO — Shoppers Drug Mart is making a $250,000 donation to support The Blueprint for Pharmacy Implementation Strategy, a long-term initiative designed to catalyze, coordinate and facilitate the changes required to align pharmacy practice with the healthcare needs of Canadians.

Shoppers Drug Mart’s donation will be designated to funding strategic research to evaluate the impact of healthcare policies on pharmacy practices.

"The expansion of pharmacy practice and implementation of government-funded pharmacy services, such as medication reviews, is a significant step forward for pharmacy," stated Domenic Pilla, president and CEO of Shoppers Drug Mart. "This research will provide further evidence of the impact that patient-centered pharmacy services have on improving health outcomes for Canadians, while at the same time easing the burden on our healthcare system."

The Blueprint for Pharmacy is a collaboration of pharmacy stakeholders, led by the Canadian Pharmacists Association and the Canadian Association of Chain Drug Stores, and supported by pharmacy organizations across Canada, working to bring about significant and meaningful change to the profession and practice of pharmacy. In 2008, the document "Vision for Pharmacy" was released, which detailed optimal drug therapy outcomes for Canadians through patient-centered care. Building on that vision, the Implementation Plan for the Blueprint for Pharmacy was developed in 2009.

"An enormous effort by all stakeholders, including Shoppers Drug Mart, has seen so much being accomplished to date," added Dennis Gorecki, chairman of the Blueprint for Pharmacy Steering Committee. "The Blueprint for Pharmacy is, however, now at the critical implementation stage, which requires essential funding to ensure the successful completion of many important projects that will help drive the evolution of pharmacy practice. We are most grateful to Shoppers Drug Mart for their leadership and for stepping up to provide continued funding to help complete these projects, and we hope that this donation will motivate other pharmacy stakeholders to also support this important initiative."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Reports: Fla. pharmacists hope to administer pneumonia, shingles shots

BY Alaric DeArment

NEW YORK — Pharmacists in Florida are hoping to expand the kinds of vaccinations they can administer, according to published reports.

Tallahassee, Fla., CBS affiliate WTSP reported that a bill proposed in the state legislature would allow pharmacists to administer shots to prevent pneumonia and shingles. While pharmacists in Florida have been able to administer flu shots since 2007, the state remains one of the few where they can’t administer pneumonia and shingles shots.

A committee in the state House of Representatives voted in favor of the bill, WTSP reported.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Amgen acquiring Micromet for $1.16 billion

BY Alaric DeArment

THOUSAND OAKS, Calif. — Drug maker Amgen is acquiring a Rockville, Md.-based company developing therapies for cancer, the companies said Thursday.

Amgen announced plans to buy Micromet for $1.16 billion, or $11 per share. Micromet, originally founded in Germany, is developing blinatumomab, currently in phase-2 trials as a treatment for acute lymphoblastic leukemia and non-Hodgkin’s lymphoma. The acquisition also will include the company’s research and development center in Munich.

"The acquisition of Miromet is an opportunity to acquire an innovative oncology asset with global rights, and a validated technology platform with broad potential clinical applications," Amgen chairman and CEO Kevin Sharer said. "Blinatumomab will serve as an important complement to our oncology pipeline and is representative of our corporate strategy, which is focused on developing and successfully commercializing therapeutics to treat patients with grievous illnesses."

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES